Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma: Mansi R. Shah, MD

The hematologist/oncologist from Rutgers Cancer Institute of New Jersey discussed ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Mansi R. Shah, MD, hematologist/oncologist, Rutgers Cancer Institute of New Jersey, assistant professor of medicine and attending, Rutgers Robert Wood Johnson Medical School, to learn more about ongoing research examining the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma.

Many clinical trials are available to patients with relapsed or refractory disease at the Rutgers Cancer Institute of New Jersey, including a study examining cilta-cel, according to Shah. Idecabtagene vicleucel (ide-cel; Abecma) is currently the only CAR T-cell therapy that is FDA approved for this patient population and wait lists to receive this product are long because the demand for this treatment has outweighed the supply, Shah says.

Cilta-cel is available to patients in a clinical trial setting for use in different lines of therapy, Shah adds. The trial that is being done at the instate provides patients with the opportunity to receive treatment with the novel modality, Shah concludes.

Related Videos
Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
Related Content
© 2023 MJH Life Sciences

All rights reserved.